SG Americas Securities
RAPP

SG Americas Securities’s Rapport Therapeutics RAPP Stock Holding History

SG Americas Securities’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,776
Closed -$118K – 3721
2026
Q1 		$118K Sell
3,776
-5,897
-61% -$166K ﹤0.01% 2876
2025
Q4 		$293K Buy
9,673
+3,408
+54% +$94.3K ﹤0.01% 2763
2025
Q3 		$186K Buy
+6,265
New +$112K ﹤0.01% 2790
2024
Q4 		– Sell
-4,934
Closed -$101K – 3707
2024
Q3 		$101K Buy
+4,934
New +$106K ﹤0.01% 3077

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

SG Americas Securities's RAPP Position: Q2 2026 in Review

SG Americas Securities sold out of Rapport Therapeutics (RAPP) in Q2 2026, closing a stake of 3,776 shares — an estimated $118K sold.

SG Americas Securities first reported a position in RAPP in Q3 2024 and held it in 4 quarters. The position peaked at $293K in Q4 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • SG Americas Securities reported no remaining Rapport Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 3,776 Rapport Therapeutics shares in Q2 2026, an estimated $118K.
  • SG Americas Securities first reported a position in Rapport Therapeutics in Q3 2024 and held it in 4 quarters.
  • SG Americas Securities's Rapport Therapeutics position peaked at $293K in Q4 2025.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.